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INTRODUCTION
Demyelinating disorders of CNS are characterized by inflammation and selective 
destruction of  central  nervous system (CNS) myelin.  The peripheral  nervous system 
(PNS) is spared and most patients have no evidence of an associated systemic illness. 
Inflammatory demyelinating diseases of the central nervous system occur through out 
the world and are  the  foremost  cause  of  the nontraumatic  neurological  disability  in 
young adults.
Multiple  sclerosis  is  the  most  common  of  these  disorders.  .  This  enigmatic, 
relapsing, and often eventually progressive disorder of the white matter of the central 
nervous  system  continues  to  challenge  investigators  trying  to  understand  the 
pathogenesis of the disease and prevent its progression.(1) 
 Multiple  sclerosis  (MS)  is  characterized  by  a  triad  of  inflammation, 
demyelination,  and  gliosis  (scarring);  the  course  can  be  relapsing-remitting  or 
progressive.  Lesions  of  MS typically  occur  at  different  times  and  in  different  CNS 
locations. Multiple  sclerosis  typically  begins  in  early  adulthood  and  has  a  variable 
prognosis. Manifestations of MS vary from a benign illness to a rapidly evolving and 
incapacitating disease requiring profound lifestyle adjustments. Fifty percent of patients 
will need help walking within 15 years after the onset of disease. 
Advanced  magnetic  resonance  imaging  (MRI)  and  spectroscopy  may  allow 
clinicians to follow the pathological progression of the disease and monitor the response 
to treatment.The visible  T2 lesions are diagnostically valuable and may allow earlier 
diagnosis  of  the disease and more accurate  prognostication(2).   Recent  progress has 
occurred in understanding the cause, the genetic components, and the pathologic process 
of multiple sclerosis. The short-term clinical and MRI manifestations of disease activity 
have been reduced by new therapies, although the degree of presumed long-term benefit 
from these treatments will require further study. 
 However Multiple Sclerosis  represents only one member of a family of CNS 
idiopathic  inflammatory  demyelinating  diseases  which  also  include  acute  transverse 
myelitis,  Acute  disseminated  encephalomyelitis,  (ADEM)  and  Neuromyelitis  optica 
(Devics disease). Although these disorders are all similarly characterized by focal CNS 
demyelination  they   vary  in  their  clinical  course,  prognosis,  regional  distribution, 
pathology and pathogenesis. 
AIM OF THE STUDY
1.To study the clinical presentation and course of different demyelinating    
      diseases   of CNS.
2. To find out the prevalence of primary and secondary demyelinating
      disease of CNS  in adult patients.
3. To correlate the MRI abnormalities and clinical disability in patients.
4. Short term follow up of  patients.
 
REVIEW OF LITERATURE
CLASSIFICATION OF DEMYELINATING DISEASES: 
              The aetiology of most demyelinating disorders is unknown. In some cases 
genetical factors are involved; others may follow viral infections such as measles and 
small  pox  or  vaccination,  and  demyelination  or  destruction  of  nerve  fibres  and 
surrounding myelin occurs in a wide variety of disorders involving the nervous system
           Demyelination can be regarded as either primary or secondary. The primary form 
destroys or damages myelin or myelin-forming cells and axons are relatively normal, at 
least in the early stages. Secondary demyelination, on the other hand, causes damage to 
neurons or axons, followed by breakdown of myelin.            
Current  classification  depends  upon  a  mixture  of  clinical  and  pathological 
features,  including  genetics,  biochemical  and  immunological  abnormalities.  Some 
metabolic defects influence the formation of myelin rather than damage to myelin once 
it has been formed. The group of diseases associated with specific metabolic defects 
influencing the formation of myelin have now been separated under the general term 
"dysmyelinating disorders or leukodystrophies".
Table : 1
Disorders That Can Cause CNS Demyelination 
Category Disorders 
Hereditary 
disorders
Phenylketonuria and other aminoacidurias
Tay-Sachs, Niemann-Pick, and Gaucher's diseases
Hurler's syndrome
Krabbe's disease and other leukodystrophies
Adrenoleukodystrophies
Adrenomyeloneuropathy
Leber's hereditary optic atrophy and related mitochondrial disorders
Hypoxia and 
ischemia
Carbon monoxide toxicity and other syndromes of delayed hypoxic 
cerebral demyelination
Progressive subcortical ischemic demyelination
Nutritional 
deficiencies
Central pontine myelinolysis (may also be caused by Na fluxes)
Demyelination of the corpus callosum (Marchiafava-Bignami 
disease)
Vitamin B12 deficiency
Direct viral 
invasion of 
CNS
Progressive multifocal leukoencephalopathy
Subacute sclerosing panencephalitis
Tropical spastic paraparesis/HTLV-1–associated myelopathy
Primary 
demyelinatin
g disorders
Recurrent, progressive disorders (multiple sclerosis and its variants)
Monophasic disorders such as optic neuritis, acute transverse 
myelitis, acute disseminated encephalomyelitis, and acute 
hemorrhagic leukoencephalitis
Neuromyelitis optica
.MULTIPLE SCLEROSIS
More than 100 years has passed since Charcot, Carswell, 
Cruveilhier,  and  others   described  the  clinical  and  pathological  characteristics  of 
multiple  sclerosis(3).  Multiple  sclerosis  (MS)  is  characterized  by  a  triad  of 
inflammation,  demyelination,  and  gliosis  (scarring);  the  course  can  be  relapsing-
remitting or progressive.
AGE DISTRIBUTION:
Multiple sclerosis is a disease of young adults; the mean age of onset is 29-33 
years, but the range of onset is extremely broad from approximately 10-59 years.
SEX DISTRIBUTION:   
Women  are  more  likely  to  develop  multiple  sclerosis  than  men,  with  MS 
occurring 
 50% more frequently in women than in men. 
GENETIC FACTORS:
 The concordance rate of 31 percent among monozygotic twins is approximately 
six times the rate among dizygotic twins (5 percent)(4). The absolute risk of the disease 
in  a  first-degree  relative  of  a  patient  with  multiple  sclerosis  is  less  than  5  percent; 
however, the risk in such relatives is 20 to 40 times the risk in the general population(5).  
Since  1973,  it  has  been  recognized  that  the  presence  of  the  HLA-DR2  allele 
substantially increases the risk of multiple sclerosis.(6)
PATHOLOGICAL FEATURES AND PATHOGENESIS:
Multiple sclerosis is generally believed to be an immune- mediated disorder that 
occurs  in  genetically  susceptible  people,(7).  The  pathological  hallmark  of  chronic 
multiple  sclerosis  is  the  demyelinated  plaque,  which  consists  of  a  well-demarcated 
hypocellular area characterized by the loss of myelin, relative preservation of axons, and 
the formation of astrocytic scars . 
Lesions have a predilection for the optic nerves, periventricular white matter, brain stem, 
cerebellum,  and  spinal  cord  white  matter,  and  they  often  surround  one  or  several 
medium-sized vessels. Although the lesions are usually round or oval, they often have 
finger-like extensions along the path of small or medium-sized blood vessels (Dawson’s 
fingers). 
Inflammatory cells are typically perivascular in location, but they may diffusely 
infiltrate the parenchyma. The  inflammatory infiltrate is composed of lymphocytes and 
macrophages; the latter predominate in active lesions. Identifying myelin-degradation 
products in macrophages is the most reliable method of identifying active lesions (8). 
             Furthermore, the lesions of chronic multiple sclerosis reportedly contain 
substantial  numbers  of  oligodendrocyte  precursor  cells.(9)  Activated  CD4+  T  cells 
specific for one or more self antigens are believed to adhere to the luminal surface of 
endothelial cells in central nervous system venules and migrate into the central nervous 
system at the time of disruption of the blood–brain barrier. This process is followed by 
an amplification of  the immune response  after  the recognition of  target  antigens on 
antigen-presenting cells. The existence of T cells that are reactive to several putative self 
myelin and non-myelin “multiple sclerosis antigens,” including myelin basic protein, 
myelin-associated  glycoprotein,  myelin  oligodendrocyte  glycoprotein,  proteolipid 
protein, B-crystallin, phosphodiesterases, and S-100 protein, has been proposed.(10-12).
 Additional amplification factors including autoantibodies or cytokines may also 
be  necessary  to  produce  the  demyelinated  plaque  (13)  Antibodies  against  antigens 
located on the surface of the myelin sheath or oligodendrocyte can cause demyelination 
directly,  possibly  through  the  activation  of  complement,  leading  to  complement-
mediated cytolysis. (14) Antibodies against both myelin oligodendrocyte glycoprotein 
and myelin basic protein can be found in the brains of patients with multiple sclerosis.  
(15). Deposits of immunoglobulin and activated complement may be present in multiple 
sclerosis lesions in which myelin is being degraded. (16)
Other  factors  potentially  toxic  to  oligodendroglial  cells  include  soluble  T-cell 
products (such as perforin), the interaction of Fas antigen with Fas ligand, cytotoxicity 
mediated by the interaction of  CD8+ T cells  with class  I  major-  histocompatibility-
complex  (MHC)  antigens  on  antigen-presenting  cells,  and  persistent  viral 
infection(17).Human herpesvirus  type  6  can  cause  a  condition  that  mimics  multiple 
sclerosis (18). and appears in oligodendrocytes within multiple sclerosis tissue in some 
patients, but not in control tissue(19).
MRI and spectroscopy may be helpful in characterizing the underlying pathologic 
processes in multiple sclerosis(20). Monitoring by means of serial MRI studies with 
gadolinium enhancement helps to identify agents that may be active against this early 
inflammatory  stage of  multiple  sclerosis  (e.g.,  corticosteroids,  interferons,  glatiramer 
acetate, and certain immunosuppressive agents).(21-25) There is MRI and pathological 
evidence that the normal-appearing white matter is not normal in patients with multiple 
sclerosis.(26-28). 
Possible Mechanisms of Injury and Repair in Multiple Sclerosis
Fig : 1
Photomicrographs of a Chronic Multiple Sclerosis Plaque  .  hypocellular region of   
myelin loss is evident in the periventricular white matter
Fig : 2
Photomicrographs of an Actively Demyelinating Multiple Sclerosis Lesion at the 
active edge of a multiple sclerosis plaque (indicated by the asterisk), the products of 
myelin degradation are present in numerous macrophages (arrowheads). Fig : 3
CLINICAL COURSE AND DIAGNOSIS:
In  relapsing–remitting multiple sclerosis — the type present in 80 percent of 
patients — symptoms and signs typically evolve over a period of several days, stabilize, 
and then often improve, spontaneously or in response to corticosteroids, within weeks. 
Relapsing–remitting multiple sclerosis typically begins in the second or third decade of 
life and has a female predominance of approximately 2:1. Persistent signs of central 
nervous system dysfunction may develop after a relapse, and the disease may progress 
between  relapses  (secondary  progressive  multiple  sclerosis).  Twenty  percent  of 
affected patients have  primary progressive multiple sclerosis, which is characterized 
by  a  gradually  progressive  clinical  course  and  a  similar  incidence  among  men  and 
women. 
Relapsing–remitting multiple sclerosis typically starts with sensory disturbances, 
unilateral optic neuritis, diplopia (internuclear ophthalmoplegia), Lhermitte’s sign (trunk 
and limb paresthesias evoked by neck flexion), limb weakness, clumsiness, gait ataxia, 
and neurogenic bladder and bowel symptoms. Many patients describe fatigue that  is 
worse  in  the  afternoon  and  is  accompanied  by  physiologic  increases  in  body 
temperature.  The  onset  of  symptoms  post  partum and  symptomatic  worsening  with 
increases in body temperature (Uhthoff’s phenomenon ) and pseudoexacerbations with 
fever  suggest  the  diagnosis.  Some  patients  have  recurring,  brief,  stereotypical 
phenomena (paroxysmal pain or paresthesias, trigeminal neuralgia, episodic clumsiness 
or dysarthria, and tonic limb posturing) that are highly suggestive of multiple sclerosis. 
Prominent cortical signs (aphasia, apraxia, recurrent seizures, visual-field loss, and early 
dementia) and extrapyramidal phenomena (chorea and rigidity) only rarely dominate the 
clinical  picture.  Eventually,  cognitive  impairment,  depression,  emotional  lability, 
dysarthria,  dysphagia,  vertigo,  progressive  quadriparesis  and  sensory  loss,  ataxic 
tremors, pain, sexual dysfunction, spasticity, and other manifestations of central nervous 
system dysfunction may become troublesome.
Patients  who have primary progressive multiple  sclerosis  often present  with a 
slowly  evolving  uppermotor  neuron  syndrome  of  the  legs  (“chronic  progressive 
myelopathy”).  Typically,  this  variant  worsens  gradually,  and  quadriparesis,  cognitive 
decline, visual loss, brain-stem syndromes, and cerebellar, bowel, bladder, and sexual 
dysfunction may develop. 
The diagnosis is  based on established clinical  and, when necessary,  laboratory 
criteria-Mac Donalds criteria(28).
MAC DONALDS CRITERIA : Table : 2
Clinical presentation Additional evidence required for 
diagnosis of MS
Two or more attacks separated in 'time' 
(at least 3 months apart) and 'space' 
(involving different parts of the CNS) 
with objective clinical evidence of two 
or more lesions
None
Two or more attacks separated in 'time' 
and 'space', but with objective clinical 
evidence for only one lesion
MRI demonstrates dissemination in 'space' 
(multiple lesions in severaldifferent sites)
or
Two or more MRI-detected lesions 
consistent with MS and oligoclonal bands 
in CSF or
Await further clinical attack at different 
anatomical site
One attack with objective clinical 
evidence of two or more lesions in 
different parts of the CNS (i.e. 
dissemination in 'space')
Dissemination in 'time', demonstrated by 
serial MRI scans (looking for a new lesion 
developing at least 3 months after the 
inital presentation) or
Await further (second) clinical attack at 
different anatomical site
One attack with clinical evidence of 
only one lesion (clinically isolated 
syndrome)
MRI demonstration of dissemination in 
'space' and 'time' (as above)  or
Two or more MRI-detected lesions with 
CSF showing oligoclonal bands and 
dissemination in time, demonstrated by 
MRI or
Await further (second) clinical attack at 
different anatomical site
Insidious neurological progression 
suggestive of MS
CSF positive for oligoclonal bands
and
Dissemination in 'space' and 'time' on MRI 
and/or abnormal VER3
or Continued progression for a year
Clinically isolated idiopathic inflammatory demyelinating diseases  such as 
optic neuritis(ON) , ATM, and tumefactive demyelinating lesions have the potential to 
convert to relapsing -remittig MS(RRMS). currently available disease modifying drugs 
delay the conversion to definite MS. This delay may be more prominent for patients who 
present with ATM than for patients who present with ON. Following an acute episode of 
complete  ATM  with  longitudinal  spinal  cord  lesions  ,  there  is  40%  chance  of 
devolepment of NMO at one year which can be predicted by the presence of specific 
antibody marker , NMO Immunoglobulin IgG.
INVESTIGATIONS:
Advances in cerebrospinal fluid analysis and MRI, in particular, have simplified 
the diagnostic process(29). The relapsing forms are considered clinically definite when 
neurologic dysfunction becomes “disseminated in space and time .On MRI, findings of 
multifocal lesions of various ages, especially those involving the periventricular white 
matter,  brain  stem,  cerebellum,  and  spinal  cord  white  matter,  support  the  clinical 
impression.  The presence of  gadolinium-enhancing lesions  on MRI indicates  current 
sites of presumed inflammatory demyelination (active lesions). When there is diagnostic 
uncertainty, repeated MRI after several months may provide evidence that the lesions 
are “disseminated in time.” 
Physiologic evidence of subclinical  dysfunction of  the optic  nerves and spinal 
cord (changes in visual evoked responses and somatosensory evoked potentials) may 
provide support for the conclusion that there is “dissemination in space.”(30). Therefore, 
spinal MRI and evoked-potential testing may provide evidence of a second lesion that 
can confirm the diagnosis. Abnormalities detected by testing of somatosensory evoked 
potentials and spinal MRI may clarify the diagnosis in patients with optic neuritis alone 
or isolated brain-stem abnormalities and in those suspected of having unifocal cerebral 
multiple sclerosis on the basis of MRI. Patients who have a so-called clinically isolated 
syndrome (e.g., optic neuritis, brain-stem dysfunction, or incomplete transverse myelitis) 
as their first event have a greater risk of both recurrent events (thereby confirming the 
diagnosis  of  clinically  definite  multiple  sclerosis)  and  disability  within  a  decade  if 
changes are seen in clinically asymptomatic regions on MRI of the brain, three or more 
T2 weighted lesions in MRI the risk of devoleping MS after 10 years is 70 – 80% (31) 
The presence of oligoclonal bands in cerebrospinal fluid slightly increases the risk of 
recurrent disease.(32)
The total  volume of T2-weighted signal  abnormality  (the "burden of disease") 
shows a significant (albeit weak) correlation with clinical disability, as do measures of 
